IARCON3549 20230827000000 iarcin:iarcin m.arslansohail@gmail.com IARCON INTERNATIONAL LLP Scientific Research Journal of Pharmacy Sci. Res. J. Pharm. 2788-9564 DOI : 10.47310/srjp https://www.iarconsortium.org/srjp/ 08 27 2023 08 27 2023 03 02 DOI : 10.47310/srjp.2023.v03i02 https://www.iarconsortium.org/srjp/archives/56/239/ Oxidative Stress in Breast and Ovarian Cancer Ayad Adnan Sahib Esraa S. Al- Fatlawey Alyaa Muqdad Mohsin Sarah Ihsan Hameed Mayameen Asaad Hbib Fatima SalehAbbas Cancer is the second-biggest cause of mortality globally. In 2018 alone, it was documented that nearly 9.6 million fatalities occurred because of cancer, in the ratio of one to six. The current study sought to establish whether oxidative stress occurs in breast and ovarian malignancies. The samples were collected from the tumor centers in Najaf from women who suffer from the required condition. The level of MDA in ovarian cancer patients was not significantly different from that of healthy women or ovarian vs. breast cancer patients. Patients with breast cancer had considerably greater amounts of lipid peroxidation products than healthy controls. Catalase activity in patients with ovary tumors was not different from that of the breast; however, there was a significant difference in catalase activity between patients with breast and ovarian cancers when compared to controls. In conclusion, the findings of present study indicate that oxidative stress is elevated in cancer patients, as seen by increased MDA and reduced catalase serum levels. 08 27 2023 08 27 2023 1 3 DOI : 10.47310/srjp.2023.v03i02.003 https://www.iarconsortium.org/srjp/56/239/602_Oxidative_Stress_in_Breast_and_Ovarian_Cancer/